Guaifenesin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Guaifenesin: From Chest Congestion to Nasal Cavity Disease
One-Sentence Summary
Guaifenesin is a widely used expectorant for productive cough and chest congestion. The TxGNN model predicts it may be effective for Nasal Cavity Disease (specifically chronic rhinitis), with 1 completed pilot clinical trial and 2 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Expectorant for productive cough / chest congestion (long-established OTC use; not derived from a South African license, as none is currently registered) |
| Predicted New Indication | Nasal Cavity Disease (chronic rhinitis) |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L2 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for this product. Based on known pharmacology, guaifenesin is an expectorant that stimulates respiratory tract gland secretion, reduces mucus viscosity, and promotes mucociliary clearance. Its efficacy in productive cough and chest congestion is well established through decades of clinical use.
Nasal cavity disease (chronic rhinitis) shares the same underlying problem of retained, viscous mucus and impaired mucociliary clearance in the airway mucosa. Since guaifenesin’s expectorant action is not anatomically restricted to the lower airway, it is mechanistically plausible that reducing mucus viscosity could also relieve nasal secretion retention — which is the rationale reflected in the one pediatric pilot trial identified below.
However, the only direct clinical evidence is a small (n=30), single pilot Phase 2 study, and the supporting literature consists of older review articles that discuss guaifenesin only as an adjunct in sinusitis/rhinitis management rather than as a primary, confirmatory data source.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01364467 | Phase 2 | Completed | 30 | Randomized, placebo-controlled pilot study of oral guaifenesin for pediatric chronic rhinitis (ages 7–18); assessed nasal symptom relief via SN-5 survey, nasal airway volume, and secretion biophysical properties over 14 days. Small single-site pilot; not yet confirmatory. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9065342 | 1997 | Review | American Journal of Rhinology | Management review of sinusitis in adult cystic fibrosis; discusses supportive care approaches including mucolytic/expectorant agents in chronic sinus disease. |
| 12487405 | 2002 | Review | Logopedics, Phoniatrics, Vocology | Review of hidden respiratory allergies in voice users; notes guaifenesin-containing decongestants as a treatment option alongside allergy management. |
South Africa Market Information
Guaifenesin currently has no registered SAHPRA licenses (0 registrations; market status: Not marketed). No product-specific registration, dosage form, or approved indication text is available for South Africa at this time.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
(Note: safety warnings, contraindications, and drug-interaction data for this candidate are currently unavailable and are flagged internally as a Blocking data gap for the safety assessment stage.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- Evidence is limited to a single small pilot Phase 2 RCT (n=30) and two older, indirect review articles — insufficient to support progression on its own.
- The drug is not currently registered or marketed in South Africa (0 SAHPRA licenses), and safety/PI data needed for an initial safety assessment is entirely unavailable, which blocks further evaluation.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (warnings, contraindications, drug interactions)
- Detailed mechanism of action documentation
- A larger, confirmatory RCT in chronic rhinitis/nasal cavity disease beyond the existing pediatric pilot
- Confirmation of a regulatory pathway or registration route in South Africa
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.